WuXi PharmaTech (NYSE: WX), a
leading pharmaceutical, biotechnology, and medical-device research and
development outsourcing company, with operations in China and the United
States, announced that it had been selected for the Deloitte Technology Fast
500 Asia Pacific 2009 List, the only company in China to receive this award
for the past six years. The Deloitte program recognizes technology companies
in the Asia Pacific region that have achieved the highest rates of revenue
growth during the preceding three years.
"We are pleased and honored to receive this award again," said Dr. Ge Li,
Chairman and Chief Executive Officer of WuXi PharmaTech. "It speaks to the
soundness of our long-term business model and the effort, talent, and customer
focus of our scientists. At WuXi PharmaTech, we continue to expand our
pharmaceutical R&D service capabilities and capacity to best serve our
customers and to sustain long-term revenue growth."
From Discovery Biology to ELRIG Chair: A Conversation with Melanie Leveridge